Cefpodoxime
Cefpodoxime is a third-generation oral cephalosporin antibiotic with broad-spectrum activity. It works by inhibiting bacterial cell wall synthesis (binding to penicillin-binding proteins), is bactericidal, and is used for respiratory, urinary, and skin infections.
Searching sources...
Reading File
Finding Sources
Searching PubMed
cefpodoxime clinical use spectrum
Reading File
Reading File
Reading File
Reading File
Reading File
Here is a detailed profile of Cefpodoxime drawn from Katzung's Pharmacology (16th ed.), The Harriet Lane Handbook (23rd ed.), and other clinical references:
Cefpodoxime (Cefpodoxime Proxetil)
Brand name: VANTIN (previously; now generics only)
Class: Third-generation oral cephalosporin - β-lactam antibiotic
Mechanism of Action
Cefpodoxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. This results in bactericidal activity. It is a prodrug - cefpodoxime proxetil is an ester form that undergoes de-esterification in the GI tract to release the active cefpodoxime.
Antimicrobial Spectrum
As a third-generation cephalosporin, cefpodoxime has expanded gram-negative coverage compared to earlier generations (Katzung, 16th ed.):
Gram-positive:
- Streptococcus pneumoniae (oral 3rd-gen agents retain activity but less than ceftriaxone/cefotaxime)
- Streptococcus pyogenes (Group A strep)
- Staphylococcus aureus (MSSA) - moderate activity; poor against MRSA
Gram-negative:
- Haemophilus influenzae (including β-lactamase-producing strains)
- Moraxella catarrhalis
- Neisseria gonorrhoeae
- E. coli, Klebsiella pneumoniae, Proteus mirabilis
- Citrobacter, Serratia marcescens, Providencia
Limitations:
- No activity against Pseudomonas aeruginosa
- Not reliable against Enterobacter spp. (inducible AmpC β-lactamase)
- Susceptible to ESBL-producing organisms
- Poor against anaerobes
Compared to cefixime, cefpodoxime has better activity against pneumococci and S. aureus - cefixime is much less active against these organisms. - Katzung's Basic and Clinical Pharmacology, 16th ed.
Pharmacokinetics
| Parameter | Details |
|---|---|
| Route | Oral only |
| Prodrug | Yes - proxetil ester, hydrolyzed in GI tract |
| Food effect | Tablets: take WITH food (enhances absorption); suspension may be given without regard to food |
| Renal excretion | Yes - dose adjustment required in renal failure |
| Half-life | ~2-3 hours |
Drug Interactions:
- Antacids / H2 blockers (high dose): Reduce absorption of cefpodoxime - avoid or separate
- Probenecid: Increases serum cefpodoxime levels (blocks tubular secretion)
Clinical Indications & Dosing
Pediatric (2 months - 11 years) - Harriet Lane Handbook, 23rd ed.
| Indication | Dose | Duration |
|---|---|---|
| Otitis media | 10 mg/kg/24 hr PO ÷ Q12h | 5-10 days; max 400 mg/24 hr |
| Pharyngitis/tonsillitis | 10 mg/kg/24 hr PO ÷ Q12h | 5-10 days; max 200 mg/24 hr |
| Acute maxillary sinusitis | 10 mg/kg/24 hr PO ÷ Q12h | 10 days; max 400 mg/24 hr |
Adult (≥12 years) - Harriet Lane Handbook, 23rd ed.
| Indication | Dose | Duration |
|---|---|---|
| Exacerbation of chronic bronchitis | 400 mg/24 hr PO ÷ Q12h | 10 days |
| Community-acquired pneumonia | 400 mg/24 hr PO ÷ Q12h | 14 days |
| Sinusitis | 400 mg/24 hr PO ÷ Q12h | 10 days |
| Pharyngitis/tonsillitis | 200 mg/24 hr PO ÷ Q12h | 5-10 days |
| Skin/skin structure infection | 800 mg/24 hr PO ÷ Q12h | 7-14 days |
| Uncomplicated UTI | 200 mg/24 hr PO ÷ Q12h | 5-7 days |
Katzung gives the adult dose as 200-400 mg twice daily.
Adverse Effects
- Diarrhea, nausea, vomiting
- Vaginal candidiasis (superinfection)
- Transient elevation of ALT/SGPT
- False-positive urine reducing substance tests (Clinitest, Benedict's, Fehling's solution) - use enzymatic glucose oxidase tests (Clinistix, Tes-Tape) instead
- False-positive Coombs test
- Use with caution in penicillin-allergic patients (cross-reactivity ~1-2%)
Special Uses
- Gonorrhea (N. gonorrhoeae): Listed as a treatment option alongside ceftriaxone and cefixime - though ceftriaxone IM remains the preferred regimen (Red Book 2021; Quick Compendium of Clinical Pathology)
- Acute otitis media (treatment failure/penicillin-non-susceptible pneumococci): Oral cefdinir, cefpodoxime, or cefuroxime recommended as step-up therapy in addition to high-dose amoxicillin-clavulanate or IM ceftriaxone (Red Book 2021)
- Chronic rhinosinusitis with penicillin-resistant pneumococci: Combination with clindamycin is recommended (cefixime or cefpodoxime + clindamycin) - Cummings Otolaryngology
- UTI: Noted as an option for uncomplicated cystitis in young women, though clinical data for 3-day regimens are limited vs. nitrofurantoin/TMP-SMX (Comprehensive Clinical Nephrology, 7th ed.)
Recent Evidence
A 2024 systematic review on cefpodoxime pharmacokinetics (PMID 39120118) provides updated PK/PD data. A 2026 network meta-analysis (PMID 42440760) of 64 RCTs on Group A strep pharyngitis evaluates cefpodoxime among 24 antibiotics - relevant for tonsillitis dosing decisions.
Summary Mnemonic
CUPS - Cefpodoxime covers:
- Community respiratory infections (otitis, sinusitis, pharyngitis, pneumonia)
- UTI (uncomplicated)
- Prodrug (proxetil ester)
- Skin infections
This is a shared conversation. Sign in to Orris to start your own chat.